Targeting the macrophage population to reprogram or enhance TAMs into an M1-polarized, CXCL10-secreting state offers a promising new therapeutic approach, particularly for ovarian cancer subtypes like clear cell carcinoma (CCC), which are often marked by immune exclusion and poor prognosis. Here, CXCL10 is linked to ovarian cancer.